In the syngeneic CT26 mouse model, the addition of IL-7 and IFN-α mRNA did not further enhance the IL-12 mRNA-induced anti-tumor efficacy, which may be due to the saturated levels of cytokine mRNAs in the high dose (30 μg/mouse/injection). This evidence concerns the gene IFNA2 and neoplasm.